Treatment of toxoplasmosis: Current options and future perspectives-Reference-Cited by-同舟云学术

Treatment of toxoplasmosis: Current options and future perspectives

Published:2019-06 Issue: Volume:15 Page:e00036
ISSN:2405-6766
Container-title:Food and Waterborne Parasitology
language:en
Short-container-title:Food and Waterborne Parasitology

Author:

Konstantinovic Neda^ORCID,Guegan Hélène,Stäjner Tijana,Belaz Sorya,Robert-Gangneux Florence

Publisher

Elsevier BV

Subject

Epidemiology,Parasitology

Reference149 articles.

1. Screening of chemical compound libraries identified new anti-Toxoplasma gondii agents;Adeyemi;Parasitol. Res.,2018

2. Immunomodulatory therapy of visceral leishmaniasis in human immunodeficiency virus-coinfected patients;Adriaensen;Front. Immunol.,2018

3. The immunomodulatory effects of rolipram abolish drug-resistant latent phase of Toxoplasma gondii infection in a murine model;Afifi;J. Microsc. Ultrastruct.,2015

4. Drugs in development for toxoplasmosis: advances, challenges, and current status;Alday;Drug Des. Devel. Ther.,2017

5. Treating AIDS-associated cerebral toxoplasmosis - pyrimethamine plus sulfadiazine compared with cotrimoxazole, and outcome with adjunctive glucocorticoids;Arens;S. Afr. Med. J.,2007

Cited by 115 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. N-acetylglucosamine supplementation fails to bypass the critical acetylation of glucosamine-6-phosphate required forToxoplasma gondiireplication and invasion;2024-01-18

2. Zinc Oxide and Magnesium-Doped Zinc Oxide Nanoparticles Ameliorate Murine Chronic Toxoplasmosis;Pharmaceuticals;2024-01-15

3. A novel mRNA vaccine, TGGT1_278620 mRNA-LNP, prolongs the survival time in BALB/c mice with acute toxoplasmosis;Microbiology Spectrum;2024-01-11

4. Pharmacological validation of dihydrofolate reductase as a drug target in Mycobacterium abscessus;Antimicrobial Agents and Chemotherapy;2024-01-10

5. Recent Trends in Toxoplasmosis Diagnosis and Management;Rising Contagious Diseases;2024-01-05